MAPK3 and Hepatic fibrosis: In liver fibrosis patients with diabetic, blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation.